Alcohol use disorder with metabolic dysfunction is associated with adverse sleep outcomes in a US clinical cohort
Alcohol use disorder with metabolic dysfunction ist mit ungünstigen Schlafoutcomes in einer US-Klinikkohorte assoziiert
Alcohol and Alcoholism · 20.09.2026 · 61 (6)
DOI: 10.1093/alcalc/agag070 ↗Auf einen Blick
In einer US-Klinikkohorte war Schlaf mit metabolischer Dysfunktion bei AUD assoziiert. Die stärksten Zusammenhänge zeigten sich für metAUD.
Fragestellung
Sind Schlafmetriken mit metabolischer Dysfunktion bei Alkoholgebrauchsstörung in einer US-Klinikkohorte assoziiert?
Methode
Teilnehmende aus dem Natural History Protocol der NIH; Einteilung in 4 Gruppen; Schlafmessung mit PSQI; multivariate logistische Regression, adjustiert für Alter, Race, Geschlecht sowie Bildung, Einkommen und Rauchstatus.
Ergebnisse
1359 Teilnehmende; 155 HC, 397 metHC, 77 AUD und 591 metAUD. Pro Kategorie mehr Schlafstörung war die Chance für metAUD gegenüber HC höher (OR 11,71; 95 %-KI 6,90–19,86).
Schlussfolgerung der Autor:innen
Ungünstige Schlafoutcomes waren mit höherer Wahrscheinlichkeit für eine koexistierende metabolische Dysfunktion bei AUD assoziiert; Schlaf und metabolische Gesundheit sollten gemeinsam beachtet werden.
Kernaussagen
- Schlafstörung war besonders stark mit metAUD assoziiert.
- OR für metAUD gegenüber HC: 11,71 (95 %-KI 6,90–19,86).
- Auch Schlafstörung und Tagesdysfunktion waren mit schwerer MD assoziiert.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Alcohol and Alcoholism, online erschienen am 06.11.2026. Verfasst von Alexandra C Wagner und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 10 Cen…. Hauptthemen laut MEDLINE: Sleep Wake Disorders, Alcoholism, Metabolic Diseases. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, NIH HHS, National Institutes of Health.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Aim
Sleep is critical to health, yet its relationship to metabolic dysfunction (MD) in alcohol use disorder (AUD) remains understudied in US clinical populations.
Methods
1359 participants were recruited through the Natural History Protocol at the National Institutes of Health and categorized into four groups: healthy controls (HC), individuals with MD only (metHC), individuals with current AUD without MD (AUD), and individuals with both current AUD and MD (metAUD). Sleep was assessed using the Pittsburgh Sleep Quality Index (PSQI). Multinomial logistic regression models were used to test associations between sleep metrics and group status, adjusting for age, race, and sex (Model 1), and additionally for education, income, and smoking status (Model 2). Additional models examined sleep outcomes by MD severity (mild, <3; severe, ≥3 criteria) among AUD.
Results
Thousand two hundred twenty participants were included: 155 HC, 397 metHC, 77 AUD, and 591 metAUD. Adverse sleep outcomes were associated with increased odds of metHC, AUD, and metAUD groups compared to HC, with the strongest associations observed for metAUD across multiple PSQI domains. Each one-category increase in sleep disturbance was associated with an eleven-fold increase in odds of metAUD relative to HC (OR: 11.71, 95% CI, 6.90–19.86). Associations remained significant in Model 2. Sleep disturbance and daytime dysfunction were also associated with increased odds of severe MD compared to AUD-only (false discovery rate < 0.05).
Conclusions
Adverse sleep outcomes were associated with increased odds of co-occurring MD in AUD, highlighting the clinical relevance of monitoring both sleep and metabolic health and the need for targeted intervention in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, United States.
- Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, United States.
- Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Old Road, Headington, Oxford OX3 7LE, United Kingdom.
Förderung
- Intramural NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Wagner, A. C., Jung, J., Vela, C., Hui, E., Perlstein, T., Reitz, J., Sewell, L., Schwandt, M. L., Diazgranados, N., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2026). Alcohol use disorder with metabolic dysfunction is associated with adverse sleep outcomes in a US clinical cohort. Alcohol and Alcoholism, 61(6). https://doi.org/10.1093/alcalc/agag070
Vancouver
Wagner AC, Jung J, Vela C, Hui E, Perlstein T, Reitz J, et al. Alcohol use disorder with metabolic dysfunction is associated with adverse sleep outcomes in a US clinical cohort. Alcohol and Alcoholism. 2026;61(6). doi:10.1093/alcalc/agag070
BibTeX
@article{Wagner2026,
author = {Wagner, Alexandra C and Jung, Jeesun and Vela, Carolina and Hui, Emily and Perlstein, Tyler and Reitz, Joshua and Sewell, LaToya and Schwandt, Melanie L and Diazgranados, Nancy and Wagner, Josephin and Rosoff, Daniel B and Lohoff, Falk W},
title = {Alcohol use disorder with metabolic dysfunction is associated with adverse sleep outcomes in a US clinical cohort},
journal = {Alcohol and Alcoholism},
year = {2026},
volume = {61},
number = {6},
doi = {10.1093/alcalc/agag070}
}
EUVIMED